<?xml version='1.0' encoding='utf-8'?>
<document id="24839948"><sentence text="Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin."><entity charOffset="100-111" id="DDI-PubMed.24839948.s1.e0" text="midostaurin" /><entity charOffset="116-126" id="DDI-PubMed.24839948.s1.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.24839948.s1.e0" e2="DDI-PubMed.24839948.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24839948.s1.e0" e2="DDI-PubMed.24839948.s1.e1" /></sentence><sentence text="Midostaurin, a multitargeted tyrosine kinase inhibitor, is primarily metabolized by CYP3A4"><entity charOffset="0-11" id="DDI-PubMed.24839948.s2.e0" text="Midostaurin" /><entity charOffset="29-37" id="DDI-PubMed.24839948.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.24839948.s2.e0" e2="DDI-PubMed.24839948.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24839948.s2.e0" e2="DDI-PubMed.24839948.s2.e1" /></sentence><sentence text=" This midostaurin drug-drug interaction study assessed the dynamic response and clinical usefulness of urinary 6β-hydroxycortisol to cortisol ratio (6βCR) and plasma 4β-hydroxycholesterol (4βHC) for monitoring CYP3A4 activity in the presence or absence of rifampicin, a strong CYP3A4 inducer"><entity charOffset="6-17" id="DDI-PubMed.24839948.s3.e0" text="midostaurin" /><entity charOffset="111-129" id="DDI-PubMed.24839948.s3.e1" text="6β-hydroxycortisol" /><entity charOffset="133-141" id="DDI-PubMed.24839948.s3.e2" text="cortisol" /><entity charOffset="166-187" id="DDI-PubMed.24839948.s3.e3" text="4β-hydroxycholesterol" /><entity charOffset="189-193" id="DDI-PubMed.24839948.s3.e4" text="4βHC" /><entity charOffset="256-266" id="DDI-PubMed.24839948.s3.e5" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e0" e2="DDI-PubMed.24839948.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e0" e2="DDI-PubMed.24839948.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e0" e2="DDI-PubMed.24839948.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e0" e2="DDI-PubMed.24839948.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e0" e2="DDI-PubMed.24839948.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e0" e2="DDI-PubMed.24839948.s3.e5" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e1" e2="DDI-PubMed.24839948.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e1" e2="DDI-PubMed.24839948.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e1" e2="DDI-PubMed.24839948.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e1" e2="DDI-PubMed.24839948.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e1" e2="DDI-PubMed.24839948.s3.e5" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e2" e2="DDI-PubMed.24839948.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e2" e2="DDI-PubMed.24839948.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e2" e2="DDI-PubMed.24839948.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e2" e2="DDI-PubMed.24839948.s3.e5" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e3" e2="DDI-PubMed.24839948.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e3" e2="DDI-PubMed.24839948.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e3" e2="DDI-PubMed.24839948.s3.e5" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e4" e2="DDI-PubMed.24839948.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24839948.s3.e4" e2="DDI-PubMed.24839948.s3.e5" /></sentence><sentence text="" /><sentence text="Forty healthy adults were randomized into groups for either placebo or treatment with rifampicin 600 mg QD for 14 days"><entity charOffset="86-96" id="DDI-PubMed.24839948.s5.e0" text="rifampicin" /></sentence><sentence text=" All participants received midostaurin 50 mg on day 9"><entity charOffset="27-38" id="DDI-PubMed.24839948.s6.e0" text="midostaurin" /></sentence><sentence text=" Midostaurin plasma pharmacokinetic parameters were assessed"><entity charOffset="1-12" id="DDI-PubMed.24839948.s7.e0" text="Midostaurin" /></sentence><sentence text=" Urinary 6βCR and plasma 4βHC levels were measured on days 1, 9, 11, and 15"><entity charOffset="25-35" id="DDI-PubMed.24839948.s8.e0" text="4βHC" /></sentence><sentence text="" /><sentence text="Both markers remained stable over time in the control group and increased significantly in the rifampicin group"><entity charOffset="95-105" id="DDI-PubMed.24839948.s10.e0" text="rifampicin" /></sentence><sentence text=" In the rifampicin group, the median increases (vs day 1) on days 9, 11, and 15 were 4"><entity charOffset="8-18" id="DDI-PubMed.24839948.s11.e0" text="rifampicin" /></sentence><sentence text="1-, 5" /><sentence text="2-, and 4" /><sentence text="7-fold, respectively, for 6βCR and 3" /><sentence text="4-, 4" /><sentence text="1-, and 4" /><sentence text="7-fold, respectively, for 4βHC"><entity charOffset="26-35" id="DDI-PubMed.24839948.s17.e0" text="4βHC" /></sentence><sentence text=" Inter- and intrasubject variabilities in the control group were 45" /><sentence text="6 % and 30" /><sentence text="5 %, respectively, for 6βCR, and 33" /><sentence text="8 % and 7" /><sentence text="5 %, respectively, for 4βHC"><entity charOffset="23-26" id="DDI-PubMed.24839948.s22.e0" text="4βHC" /></sentence><sentence text=" Baseline midostaurin area under the concentration-time curve (AUC) correlated with 4βHC levels (ρ = -0"><entity charOffset="10-21" id="DDI-PubMed.24839948.s23.e0" text="midostaurin" /><entity charOffset="84-88" id="DDI-PubMed.24839948.s23.e1" text="4βHC" /><pair ddi="false" e1="DDI-PubMed.24839948.s23.e0" e2="DDI-PubMed.24839948.s23.e0" /><pair ddi="false" e1="DDI-PubMed.24839948.s23.e0" e2="DDI-PubMed.24839948.s23.e1" /></sentence><sentence text="72; P = " /><sentence text="003), but not with 6βCR (ρ = 0" /><sentence text="0925; P = " /><sentence text="6981)" /><sentence text="" /><sentence text="Both 6βCR and 4βHC levels showed a good dynamic response range upon strong CYP3A4 induction with rifampicin"><entity charOffset="97-107" id="DDI-PubMed.24839948.s29.e0" text="rifampicin" /><entity charOffset="14-23" id="DDI-PubMed.24839948.s29.e1" text="4βHC" /><pair ddi="false" e1="DDI-PubMed.24839948.s29.e1" e2="DDI-PubMed.24839948.s29.e1" /><pair ddi="false" e1="DDI-PubMed.24839948.s29.e1" e2="DDI-PubMed.24839948.s29.e0" /></sentence><sentence text=" Because of lower inter- and intrasubject variability, 4βHC appeared more reliable and better predictive of CYP3A4 activity compared with 6βCR"><entity charOffset="55-58" id="DDI-PubMed.24839948.s30.e0" text="4βHC" /></sentence><sentence text=" The data from our study further support the clinical utility of these biomarkers" /><sentence text="" /></document>